fingolimod hydrochloride has been researched along with lysophosphatidylcholines in 6 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (lysophosphatidylcholines) | Trials (lysophosphatidylcholines) | Recent Studies (post-2010) (lysophosphatidylcholines) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 5,058 | 39 | 976 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Antel, JP; Darlington, PJ; Jarjour, AA; Kennedy, TE; Ludwin, SK; Miron, VE; Soliven, B | 1 |
| Baker, D; Giovannoni, G; Jackson, SJ | 1 |
| Dev, KK; Sheridan, GK | 1 |
| Baharvand, H; Javan, M; Yazdi, A | 1 |
| Ghasemi-Kasman, M; Hashemian, M; Parsian, H; Sadeghi, F | 1 |
| Ahmadian, SR; Ghasemi-Kasman, M; Hashemian, M; Nosratiyan, N; Parsian, H; Rostami-Mansoor, S | 1 |
6 other study(ies) available for fingolimod hydrochloride and lysophosphatidylcholines
| Article | Year |
|---|---|
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
Topics: Animals; Animals, Newborn; Astrocytes; Cerebellum; Demyelinating Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Mice; Microglia; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stem Cells; Tissue Culture Techniques | 2010 |
Fingolimod modulates microglial activation to augment markers of remyelination.
Topics: Animals; Biomarkers; Cell Culture Techniques; Cells, Cultured; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Microglia; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Myelin Sheath; Nerve Degeneration; Pregnancy; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Spheroids, Cellular; Sphingosine | 2011 |
S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures.
Topics: Animals; Animals, Newborn; Astrocytes; Cell Movement; Cerebellum; Chemokine CCL20; Chemokine CCL3; Chemokines; Demyelinating Diseases; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Lysophosphatidylcholines; Myelin Basic Protein; Neurofilament Proteins; Organ Culture Techniques; Oxadiazoles; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Thiophenes | 2012 |
Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720).
Topics: Animals; Corpus Callosum; Demyelinating Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophosphatidylcholines; Male; Mice, Inbred C57BL; Myelin Sheath; Neural Stem Cells; Neuroprotective Agents; Oligodendroglia | 2015 |
Fingolimod (FTY720) improves the functional recovery and myelin preservation of the optic pathway in focal demyelination model of rat optic chiasm.
Topics: Animals; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Histone Deacetylase 1; Lysophosphatidylcholines; Male; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Optic Chiasm; Rats; Rats, Wistar; Recovery of Function; Remyelination; Sphingosine-1-Phosphate Receptors; Valproic Acid | 2019 |
Intranasal administration of fingolimod (FTY720) attenuates demyelination area in lysolecithin-induced demyelination model of rat optic chiasm.
Topics: Administration, Intranasal; Animals; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophosphatidylcholines; Male; Optic Chiasm; Rats; Rats, Wistar | 2022 |